I often describe regulatory strategy as the invisible skeleton of a biotechnology company. When it is well-formed, you hardly notice it is there, yet it provides the essential structure that allows the scientific muscle to move and the commercial heart to beat.
During my career, I have seen brilliant science falter because the regulatory roadmap was treated as an afterthought. In the early-stage biotech environment, you do not have the luxury of a hundred-person department to catch every detail. You must be lean, strategic, and, above all, proactive. My experience has taught me that the regulatory lead should not be the person putting the brakes on development. They should be an accelerator as well as a navigator, supporting the team to move forward quickly and confidently in the right direction.
Don’t be delayed by the wait for data
One of the most common mistakes I see in early-stage firms is the desire to wait for the perfect data package before talking to a regulator. There is a misplaced fear that if you show your hand too early, you will be locked into a path you cannot change. In my experience, the opposite is true. Engaging key bodies like the FDA, EMA, and the MHRA early on is the only way to build a shared understanding of a novel modality.
At U-Ploid Biotechnologies, our lead therapeutic is designed to address the primary cause of IVF failure: age-related decline in oocyte quality. This means we are operating in a space that has been historically neglected by the drug development industry, and there is no well-trodden regulatory path for us to follow. Instead, we are collaborating closely and transparently with regulatory bodies in key jurisdictions to make sure that we are mapping out the right path together.
By initiating these conversations early, development teams are much more likely to get confirmation that their clinical program is acceptable to regulators before spending millions implementing studies that are unlikely to lead to success. This dialogue is even more critical when your pre-clinical data is compelling and momentum is building; you need to ensure the regulators are as excited by the potential paradigm shift as the scientific community (and your investors) are.
Manufacturing: the make or break
While the clinical data often gets the headlines, manufacturing scalability is the area where regulatory strategy can truly make or break a company. It is a delicate balancing act. You need a process that is robust enough for clinical trials as well as flexible enough to scale without requiring a complete redesign of your manufacturing process later.
In the world of advanced therapies and first-in-class biologics, your product is your process. If you change your manufacturing process, scale or site significantly between Phase I and Phase III, you might find yourself with data non-representative of the final process/product. I always advise companies to understand your key product attributes and align their Chemistry, Manufacturing, and Controls (CMC) milestones directly with their regulatory goals. If you are aiming for an expedited pathway, your manufacturing readiness must be accelerated too. You cannot have a fast-track clinical program paired with a slow-track manufacturing plan.
On top of this, it’s important to consider the global nature of supply chains. A regulatory strategy that ignores the specific requirements of different manufacturing jurisdictions is a strategy that will eventually hit a wall. Whether you are using a CDMO or building in-house capacity, the regulatory documentation must be as rigorous as the science itself.
Jumping into the fast lane
The rise of expedited/prioritized pathways, such as Breakthrough Therapy designation (BTD) in the US, Sagigake in Japan, Innovative Licensing and Access Pathway in UK, or the Priority Medicine Scheme (PRIME) in the EU, has changed the game for biotech. These are fantastic tools, but they are not a free pass. They require a high level of interaction with regulators and a commitment to transparency.
Choosing the right pathway involves an honest assessment of your therapeutic's impact. For U-Ploid's candidate, Lyvanta, which targets a significant unmet need in fertility, we have evidence and data to make a strong case for acceleration. But this sort of data can be difficult to acquire, and you must be prepared for the increased workload. These pathways demand more frequent data submissions and a more intensive dialogue with regulators. You should also remember that being granted a designation is just the start. It is a promise of cooperation and prioritisation, not a guarantee of approval.
The reality of regulatory divergence
During my four years as Chair of the Bioindustry Association (BIA) Regulatory Affairs Advisory Committee, I spent a lot of time thinking about the UK's post-Brexit life sciences landscape. We are now in a world where the MHRA, FDA, PMDA and EMA do not always move in lockstep. This divergence creates both challenges and opportunities.
For an Oxford-based company like U-Ploid, the UK is an incredible place to start. The MHRA has shown a real appetite for innovation and a willingness to be agile. However, a global regulatory roadmap must account for the nuances of each territory from the start. You cannot simply design a strategy for one market and hope it fits the others. Whether it is differences in age-specific requirements or specific labelling nuances, these details must be baked into your international strategy. I have found that a modular approach, where you have a core global dossier supplemented by territory-specific modules, is the most effective way to manage this complexity.
It's also really important to keep an eye on the emerging trends in real-world evidence (RWE). Key regulators including, FDA, PMDA, MHRA and EMA, have published their perspectives of use of RWE for regulatory decision making, demonstrating varying degrees of comfort with these new data sources. If your strategy relies on non-traditional data, you need to know which agency is likely to be your best partner first.
De-risking for the boardroom
Finally, we must talk about the role of regulation in investment. For an early-stage biotech, a robust regulatory roadmap is a crucial piece of de-risking proof for investors.
When I speak with the leadership team or external partners, I am often translating regulatory milestones into value inflection points. Investors are savvy. They know that science is risky – that’s very much baked into their strategy – but they have less patience for avoidable regulatory hurdles and delays. A clear, well-articulated plan for how you will get from a pre-clinical model to a human clinical trial provides the confidence they need to commit capital. It shows that you have a vision for the finish line that will ultimately deliver them a return.
A regulatory strategy should also include risk assessment and mitigation strategy. What if a trial endpoint is not met? What if a regulator asks for an additional study? Having these contingencies mapped out demonstrates a level of maturity that investors find incredibly reassuring. It proves that the company is managed by people who understand the commercial and political realities of the life sciences sector.
Finally, if you’re an early-stage biotech company preparing to move into the clinic, remember that your regulatory strategy must be rooted in three core principles:
Using early dialogue opportunities with the key global regulators to ensure a development path is efficient and aligned with agency expectations.
Considering scalability from day 1 of manufacturing process design.
Baking regulatory divergence and modular territory requirements into global strategy as powerful proof for investors that the science has a viable path to market.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
